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a  b  s  t  r  a  c  t
Ageing  is a complex  multifactorial  process  that  results  in  many  changes  in  physiological  changes  pro-
cesses  that ultimately  increase  susceptibility  to  a wide  range  of diseases.  As  such  an ageing population
is  resulting  in a pressing  need  for more  and  improved  treatments  across  an  assortment  of  diseases.  Such
treatments  can  come  from  a  better  understanding  of  the  pathogenic  pathways  which,  in  turn,  can  be
derived  from  models  of  disease.  Therefore  the more  closely  the  model  resembles  the  disease  situation
the  more  likely  relevant  the  data  will  be that  is generated  from  them.  Here  we  review  the  state  of  knowl-
edge  of  mouse  models  of a range  of diseases  and  aspects  of  an  ageing  physiology  that  are  all  germanegeing
henotyping
to  ageing.  We  also give  recommendations  on the  most  common  mouse  models  on  their relevance  to the
clinical  situations  occurring  in aged patients  and  look  forward  as  to how  research  in  ageing  models  can
be  carried  out.  As we continue  to elucidate  the  pathophysiology  of  disease,  often  through  mouse  models,
we also  learn  what  is  needed  to reﬁne  these  models.  Such  factors  can  include  better  models,  reﬂecting
the  ageing  patient  population,  or a better  phenotypic  understanding  of  existing  models.
©  2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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. Introduction
The utility of the mouse in aiding our understanding of disease is
lear; the ability to manipulate its genome, a short breeding cycle,
eﬁned genetic backgrounds, and the array of phenotypic inter-
ogations available for the mammalian physiology have all helped
lucidate the pathogenesis of disease. Whilst ageing is a risk fac-
or for a range of diseases (Niccoli and Partridge, 2012) and there
re many efforts to understand the effect of ageing through the
odulation of ageing itself (Fontana et al., 2010; Guarente, 2014)
t is also clear many diseases have a signiﬁcant genetic component.
his genetic susceptibility may  be exacerbated in the context of
n ageing physiology, thereby resulting in the observed increased
isease risk with age. Thus, the study of individual disease path-
ays through speciﬁc mouse models could aid our understanding
f not only disease but also the increased risk associated with age-
ng. Studies in young mice are often fruitful, but to understand
isease, model it accurately, and subsequently test interventions it
s only logical that if one is studying a chronic or age-related disease
he best models will be chronic or have an ageing component. The
isease burden faced by the aged is wide-ranging and varies from
ndividual to individual but there are diseases that are common
mong aged patients. It is therefore a challenge in many disease
reas to include the role of ageing, which may  add additional
omplications or comorbidities that compound the underlying con-
ition (Fabbri et al., 2015). Here we highlight a subset of relevant
llnesses and how mice, young, old, and indeed with accelerated
geing, have been used to study them. In this review we highlight
he potential impacts of ageing on disease susceptibility in a range
f disease areas to emphasise the relevance of current models, and
ake suggestions for reﬁnements and new developments.
. Acute trauma and sepsis
Although traumatic injuries are not the main cause of death in
eople aged ≥60 years, traumas like falls or motor vehicle collisions
re associated with an increased mortality risk in elderly patients
Sampalis et al., 2009; Schoeneberg et al., 2014). Often, the trauma
tself is not the actual killer; most frequently, the main cause of
he ensuing morbidity/mortality in those patients are secondary
nfections rapidly progressing to sepsis and/or multiple organ dys-
unction syndrome (MODS) (Angus, 2001; Frohlich et al., 2014).
usceptibility and mortality from systemic infections increase with
atient’s age, and sepsis is among the leading causes of death in age-
ng patients worldwide (Angus, 2001; Wafaisade et al., 2011). To
tudy the above mentioned critical care conditions, the availability
f effective age modeling approaches is essential.
Regardless whether trauma or infection occurs, similar
mmuno-inﬂammatory reactions are triggered via either DAMPS
danger associated molecular patterns) or PAMPS (pathogen asso-
iated molecular patterns) (Lord et al., 2014; Boomer et al., 2014).
ith advanced age, the host’s capability to mount an adequate
mmune response against inﬂammatory stimuli declines. This phe-
omenon is apparent in humans and laboratory animals, including
ice (Frasca and Blomberg, 2015). For example, while the num-
er of B-cells and naïve T-lymphocytes decreases, T2-helper cells
producing the anti-inﬂammatory interleukins (IL) 4 and 10) accu-
ulate (Linton et al., 1996; Miller, 1996; Weksler et al., 2002).
imultaneously, ageing is associated with a persistent low-grade
ncrease of various pro-inﬂammatory and acute phase proteins,
any of which are independent predictors of mortality/morbidityn patients (Bruunsgaard et al., 2003; Giovannini et al., 2011; Harris,
999). All those immunologic changes are part of an age-related
ecline of physiologic functions termed frailty, which occurs in
oth humans and mice (Mohler et al., 2014). Thus, those simi-nd Development 160 (2016) 54–68 55
lar immuno-inﬂammatory characteristics justify the age-oriented
investigative utility of the mouse in critical care conditions.
Despite the critical need for such translational studies, preclin-
ical research addressing the mechanisms and impact of age on
immuno-inﬂammatory endpoints is infrequent. The main reason
is undoubtedly the ﬁnancial burden: aged mice must be either
purchased (e.g. D 156 for an 18-month old female CD-1 mouse) or
“matured” from a young age for 18–24 months. The latter option,
although seemingly attractive, poses many underappreciated risks
that may  eventually surpass the costs of “ready-to-use” mice (Miller
and Nadon, 2000). Despite those hurdles and recently voiced trans-
lational doubts (Seok et al., 2013), many important and ﬁndings
stem from mouse studies in critical care (Osuchowski et al., 2014).
In trauma, the majority of existing studies concentrate not on the
age itself but rather on the interplay between the age and gen-
der (Kahlke et al., 2000; Mees et al., 2007, 2008), given that sex
hormones inﬂuence the immune response and their production is
age-dependent. For example, estrogens have demonstrated strong
protective effects in sexually mature mice when subjected to sepsis
after traumatic insults (Choudhry, 2005) and to burn injuries alone
(Kovacs, 2005). A frequently used model combining laparotomy
and hemorrhagic shock (Kahlke et al., 2000; Schneider et al., 2007)
showed that, similarly to human patients (Livingston et al., 2003),
trauma affects the amount of circulating bone marrow-associated
cells in mice (Schneider et al., 2007). Moreover, the same model
demonstrated the (clinically valid) phenomenon of compartmen-
talisation of immune responses in aged mice, resulting in different
responses in distinct tissues. For example an enhanced inﬂamma-
tion in the spleen and inﬂammatory depression in peripheral blood
mononuclear cells (PBMC) can occur conincidently (Kahlke, 2000;
Schneider et al., 2006).
Recently, more sophisticated polytrauma models combining
hemorrhage with bone fractures (Kleber et al., 2015; Wichmann
et al., 1998; Wichmann, 1996), chest trauma (Seitz et al., 2011)
or cecotomy (Gentile et al., 2013) have been introduced. Their
main strength is that they more closely recapitulate the immuno-
inﬂammatory deregulations occurring in trauma patients. These
include a reduced cytokine release capacity by splenocytes, peri-
toneal macrophages (Wichmann et al., 1998; Wichmann, 1996)
and PBMCs (Seitz et al., 2011) and a loss of major histocompati-
bility complex class II and CD4+ cells (Gentile et al., 2013). Similar
immuno-inﬂammatory deﬁcits were shown to be induced in aged
mouse burn models (Kovacs et al., 2002, 2004; Plackett et al., 2003;
Nomellini et al., 2008; Plotnikov et al., 2013). Although traumatic
brain injuries (TBI) typically occurs in very young or old humans
(Langlois et al., 2006), experimental mouse studies are primarily
performed in young subjects. The only three existing TBI studies
comparing young and aged mice demonstrated higher mortality,
stronger neurological function deﬁcits and increased inﬂammatory
markers (Kumar et al., 2013; Onyszchuk et al., 2008; Timaru-Kast
et al., 2012) in the latter. The most sophisticated, and clinically
relevant, approach are so called two-hit models combining these
trauma-induced immuno-inﬂammatory deregulations (e.g. after
ﬁrst-hit hemorrhage, laparotomy, and/or bone fracture insult) and
infections/sepsis as a delayed second hit (see below) (Seitz et al.,
2011; Gentile et al., 2013; Kovacs et al., 2002, 2004). The most com-
monly used trauma models and their application in aged animals
are listed in Table 1.
Sepsis can originate from many sites in the body, most fre-
quently the lungs, abdomen, urogenital tract and iatrogenic sources
(e.g. indwelling catheters) (Angus, 2001; Vincent, 2006) and the
elderly (and neonates) are most at risk. As our understanding of
sepsis pathophysiology and epidemiology has grown, the murine
modeling has been gradually evolving in an attempt to match the
complex clinical reality but this evolution is too slow regarding
the age component. Currently, the live bacteria pneumonias and
56 S. Drechsler et al. / Mechanisms of Ageing and Development 160 (2016) 54–68
Table 1
The most commonly used mouse models of trauma categorized by their clinical relevance and frequency in aged-oriented research use.
Trauma modela Clinical Relevanceb Tested in Aged
Micec
Relevant
Referencesd
Hemorrhagic shock Barrientos (2006) low/medium yes Seok et al. (2013),Osuchowski et al. (2014)
Hemorrhage + laparotomy medium yes Mohler et al. (2014),Miller and Nadon (2000),Mees et al.
(2007),Mees et al. (2008)
Hemorrhage + chest trauma Schneider et al. (2006) high no –
Traumatic brain injury Frank et al. (2009) high yes Plackett et al. (2003),Nomellini et al. (2008),Plotnikov et al.
(2013),Cowley et al. (2012),Kohama et al. (1995)
Chest trauma Mawhinney et al. (2011) high no –
Burn Li et al. (2009) High/very high yes Wichmann et al. (1998),Wichmann (1996),Seitz et al.
(2011),Gentile et al. (2013)
Polytrauma Kleber et al. (2015),Cowley et al. (2012) very high no Gentile et al. (2014),Lyons et al. (2009)
a Most common experimental setups are listed; listed references include selected relevant model development publications and/or review papers.
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(b Relevance of each listed model applies to a corresponding human condition.
c Mice ≥ 18 months of age.
d Maximum of 5 relevant references listed.
he cecal ligation and puncture (CLP) peritonitis are considered by
any as the most clinically relevant model systems. Both closely
imic  the protracted pathophysiologic processes (e.g. concurrent
elease of pro- and anti-inﬂammatory mediators, impaired coag-
lation/ﬁbrinolysis, and organ dysfunction) which typically occur
n sepsis patients (Saito et al., 2003; Remick et al., 2000; Esposito
nd Pennington, 1983; Angus and van der Poll, 2013; Dejager et al.,
011). Pneumonia is produced via intranasal/tracheal instillation of
arious pathogens (i.e. Pseudomonas, Klebsiella, Streptococcus pneu-
onia,  Inﬂuenza virus) (Starr and Saito, 2014; McConnell et al.,
011; Mares et al., 2010; Shivshankar et al., 2011), while CLP
nd colon ascendens stent peritonitis (CASP) induce polymicrobial
bdominal peritonitis via leakage of feces from the gut (Hubbard,
005; Zantl, 1998). Furthermore, instillation of single or double
trains of bacteria into the murine bladder produces urosepsis and
evealed the role of bacterial adhesins for retention of bacteria
n the urinary tract (Hagberg, 1983a,b). However, this model has
ot yet been tested in aged mice. Less relevant peritonitis models
nclude intraperitoneal fecal pellets, ﬁbrin clots containing fecal
acteria (Ahrenholz and Simmons, 1980; Starr et al., 2014; Gentile
t al., 2014; Nulsen et al., 1983), and injection of live/inactivated
acteria (Hyde and McCallum, 1992). Historically, the adminis-
ration of a bacterial lipopolysaccharide (LPS) has been the most
requently used experimental setup aiming to produce sepsis-like
ymptoms. The current consensus is that LPS does not recapitulate
he protracted immuno-inﬂammatory responses of human sepsis
Osuchowski et al., 2014; Remick et al., 2000).
Sepsis models can be successfully used to mimic  secondary com-
lications after trauma (i.e. two-hit models) (Drechsler et al., 2012;
acionales et al., 2015). Importantly, the clinical relevance of those
odels critically depends on the severity and mode of action of each
it. For example the more severe the initial trauma, the more likely
atients will develop secondary complications (due to dysfunc-
ional/suppressed inﬂammatory responses). Thus, when combined
ith a subsequent (two-hit) infectious insult, the relatively low-
everity ﬁrst trauma hits (e.g. hemorrhage only) appear as an
nferior choice. Given that mice possess an innate high resistance
o trauma (and inﬂammation) even severe mouse trauma models
annot recapitulate a full pallet of the most severe responses that
ccur in patients. It is equally crucial to choose an appropriate sep-
is model match (e.g. CLP for abdominal sepsis) and a suitable level
f its severity ensuring a clinically-realistic outcome proportion
e.g. approx. 30–40% mortality post-CLP). Finally, different types of
epsis frequently occur simultaneously in immunocompromised
e.g. posttraumatic) patients, thus, combination of different sep-
is models is theoretically possible. Yet, such setups appear very
urdensome (and ethically problematic) to be tested in aged mice
especially 2-hit scenarios) (Muenzer et al., 2006; Davis et al., 2011).Most common available sepsis models and their application in aged
animals are listed in Table 2.
In summary, the similar responses and age-adjusted survival
patterns (Turnbull, 2003) further emphasise the utility of well-
designed mouse modeling. The great advantage in mouse modeling
of age-related critical care disorders is that it does not require
development of new sophisticated modeling platforms solely
devoted to this purpose. Thus, the dire demand for age research
in trauma/sepsis can be met  relatively quickly: it merely requires
a thoughtful selection of the most hypothesis-ﬁtting and clinically
relevant models (from the myriad of existing variations) and their
application in aged mice, typically around 18–24 months of age.
The relatively short life time-span of the mouse (compared to larger
mammals) allows for multiple repetitions and solid veriﬁcation of
the generated data – a key component of the effective extrapolation
to human medicine.
2.1. Neuroinﬂammation
Systemic inﬂammation occurs with ageing (Frasca and
Blomberg, 2015; Franceschi and Campisi, 2014; Ostan et al., 2008)
and it is generally agreed inﬂammatory changes are characteristic
of the aged brain and are a prominent feature of most, if not all,
neurodegenerative conditions. Neuroinﬂammation is character-
ized by increased expression of inﬂammatory cytokines including
interleukin 1 beta (IL-1), tumour necrosis factor (TNF)-,  and
interleukin 6 (IL-6), and it has been known for more than two
decades that the expression of these cytokines is increased in an
age-related manner (Lynch, 2010; Godbout et al., 2005).
Microglia are the primary source of inﬂammatory cytokines
and numerous studies have reported that the increase in inﬂam-
matory cytokines is accompanied by an age-related increase in
microglial activation. Consistent with this, microarray analysis
has revealed an upregulation of genes associated with inﬂamma-
tion, including genes that are indicative of microglial activation
like major histocompatibility complex class II (MHCII) (Lee et al.,
2000; Godbout et al., 2005). Further analyses conﬁrmed the age-
related increase in MHCII and also reported increased expression
of other markers of microglial activation including CD68, CD80 and
CD86. These changes have also been conﬁrmed by immunohisto-
chemistry and ﬂow cytometry, which demonstrated an age-related
increase in CD11b+MHCII+ cells in the brain (Lynch, 2010, 2014;
Barrett et al., 2015). More recently, microarray data obtained from
analysing human post-mortem brain tissue identiﬁed age-related
changes in expression of several immune/inﬂammation genes,
especially in the hippocampus, including IL-1, IL-6 and TNF as
well as MHCII, especially in the hippocampus, an area that plays
an important role in memory. In the choroid plexus, an interface
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Table  2
The most commonly used mouse models of sepsis categorized by their clinical relevance and frequency in aged-oriented research use.
Infection/Sepsis modela Model
Complexity
Clinical
Relevanceb
Tested in
Aged Micec
Relevant
References d
Endotoxemiae Drechsler et al. (2012),Nacionales et al. (2015)
(LPS bolus)
1 hit very lowf yes Kumar et al. (2013),Davis et al.
(2011),Turnbull (2003),Franceschi and
Campisi (2014),Ostan et al. (2008)
Live/inactivated bacteriag (iv/ip administation) 1 hit;
monobacterial
low/mediumh yes Ahrenholz and Simmons (1980)
Intra-abdominal Ostan et al. (2008) 1 hit
a) Feces Hagberg (1983a) polybacterial medium yes Zantl (1998),Hagberg (1983a)
b) Fibrin clot Shivshankar et al. (2011) mono/polybacterial medium no –
c)  CASP Starr and Saito (2014) polybacterial medium no –
d)  CLP Dejager et al. (2011),Lynch (2010) polybacterial high yes Kumar et al. (2013),Drechsler et al.
(2012),Lee et al. (2000),Lynch
(2014),Barrett et al. (2015)
Urosepsis McConnell et al. (2011),Mares et al. (2010) 1 hit; mono
/polybacteriali
high no –
Pneumoniaj Timaru-Kast et al. (2012),Barrett et al. (2015) 1 hit;
monobacterial
high yes Timaru-Kast et al. (2012),Baruch et al.
(2013),Baruch et al. (2014),Maher et al.
(2006),Maher et al. (2005)
Trauma/CLP or pneumoniak Starr et al. (2014),Maher et al.
(2005),Nolan (2005)
2 hit medium/very
highl
yes Starr et al. (2014),Gentile et al. (2014)
CLP/Pneumonia or fungemia Gentile et al. (2014),Nulsen et al. (1983) 2 hit very high no –
LPS: lipolysaccharide; iv: intravenous; ip: intraperitoneal; CASP: colon ascendens stent peritonitis; CLP: cecal ligation and puncture.
mCombination of models simulating the two  most commonly occurring types of sepsis syndromes in patients; systemic candidiasis (by Candida albicans) is one of the most
common nosocomial infections in immuno-compromised sepsis patients.
a Most common experimental setups are listed; listed references include selected relevant model development publications and/or review papers.
b Relevance of each listed model applies only to a corresponding human condition (e.g. CLP to human ruptured diverticulitis/appendicitis), not across all existing sepsis
syndromes.
c Mice ≥ 18 months of age.
d Maximum of 5 relevant references listed.
e Irrespective of the administration route.
f Resemblance to fulminant meningococcemia only; not a true infection.
g Other administration routes of live bacteria are included in speciﬁc organ compartments as more clinically relevant model designs (e.g. intratracheal administration of
S.  pneumoniae).
h Relevance depends on the model design-to-hypothesis match; e.g., low relevance of an inactivated E. coli ip bolus injection to simulate peritonitis, medium relevance of
protracted iv infusion of live E. coli to simulate septic shock.
i Simultaneous administration (into the urinary bladder) of maximum 2 bacterial strains; to date, a wide-range polybacterial inoculus (e.g. feces) used in rats (Kovacs et al.,
2002) but not mice.
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l Relevance depends on the proper severity match in both hits.
etween the brain and the circulation and an important gateway
or leukocyte inﬁltration into the brain (Demeestere et al., 2015),
he anti-inﬂammatory cytokine IL-4 was elevated, whereas the pro-
nﬂammatory cytokine, interferon gamma  (IFN-)was decreased
n the aged mouse. This is indicative of a shift toward a pro-
nﬂammatory state (Baruch et al., 2013). Additionally, a chronic
geing-induced type I interferon signature was  observed at the
rain’s choroid plexus, which negatively inﬂuences brain function
Baruch et al., 2014).
Microglia share many properties of macrophages, including
heir ability to respond to numerous stimuli, reﬂecting the huge
rray of receptors expressed on their cell surface. In the past few
ears, it has become clear that microglia, like macrophages, adopt
ifferent activation states (at least in vitro) with evidence of polar-
zation to a ‘classical’ M1  phenotype in response to interferon IFN
nd an ‘alternative’ M2  phenotype in response to IL-4 and other
nti-inﬂammatory cytokines. Translation of these phenotypes into
he in vivo situation is fraught with difﬁculties but the evidence sug-
ests that IFN concentration increases with age, in contrast to the
ecrease in IL-4 (Maher et al., 2006, 2005; Nolan, 2005) suggesting
n age-related bias towards the inﬂammatory M1  phenotype. This
s also consistent with the proposal that microglia become primed
ith age, making them more susceptible to subsequent inﬂamma-
ory stimuli. Thus treatment of aged mice with LPS exerted a more
rofound effect on sickness behaviour and induced a greater pro-
uction inﬂammatory cytokines than in young mice (Godbout et al.,
005). LPS also induced a greater degree of microglial activation
nd a more profound depressive behaviour (Godbout et al., 2005). pneumoniae).
BF), acute lung injury (ALI); any order of hits is possible (e.g. H-BF/CLP; CLP/ALI).
in aged mice (compared with young). Similarly an age-related sen-
sitization to E. Coli has been reported with evidence of exaggerated
and persistent behavioral effects (Barrientos, 2006), which were
attributed to IL-1 (Frank et al., 2009). An increase in responsive-
ness to amyloid- (A),  the principal constituent of the plaques
in Alzheimer’s disease (AD), has also been reported in aged ani-
mals whereby central injection of a sub-threshold concentration
of A1−42 in young animals induced a signiﬁcant effect on IL-1
concentration in hippocampus of aged animals (Minogue et al.,
2007).
Interestingly, the evidence indicates that there is an age-related
upregulation of genes relating to activation of the inﬂammasome
(Cribbs et al., 2012); this cytosolic multiprotein complex is neces-
sary to activate caspase 1 and therefore to process IL-1 to its active
form. Consistent with this, there is an increase in the expression
of cleaved caspase 1 and pannexin 1 in the hippocampus, which
is indicative of increased inﬂammasome activation (Mawhinney
et al., 2011). It is important to note that whereas microglia may
be the primary source of inﬂammatory cytokines, astrocytes are
also capable of producing IL-6, IL-1 and TNF, albeit to a lesser
extent than microglia (Li et al., 2009) and there is clear evidence
of an increased astrocytic activation with age. Several studies have
reported increases in the archetypal marker of astrocytic activa-
tion, glial ﬁbrillary acidic protein (GFAP) (Godbout et al., 2005; Lee
et al., 2000; Cowley et al., 2012; Kohama et al., 1995; Hayakawa
et al., 2007).
When the brain is not challenged, the primary function
of microglia is surveillance; microglial processes sample their
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icroenvironment every few hours (Nimmerjahn et al., 2005) and
his surveillance state is somewhat misleadingly called the rest-
ng state. Under these conditions microglia are kept in check by
igand-receptor interactions like the interaction between CD200
nd CX3CL1 and their respective receptors that are expressed
n microglia (Lyons et al., 2007, 2009) but also by a variety of
oluble factors (Ransohoff and Perry, 2009). A decrease in the
epressive tone might contribute to microglial activation and it
as been shown that both CD200 and CXCL1 are decreased in the
ippocampus with age and coupled with evidence of microglial
ctivation. It is also worth noting that IL-4 concentration, albeit
ow under resting circumstances, is decreased in the hippocam-
us with age and IL-4-induced phosphorylation of JAK1 (janus
inase 1) and STAT6 (signal transducer and activator of transcrip-
ion 6, interleukin-4 induced) is similarly decreased (Maher et al.,
005; Nolan, 2005), whereas IL-1-associated signalling through
NK (Jun amino-terminal kinases) is increased (Nolan, 2005). These
ignalling pathways were conﬁrmed as being protective as addi-
ion of IL-4 to aged animals prevented the age related impairment
f long term potentiation (Nolan, 2005).
The age-related glial activation and increased hippocampal
xpression of inﬂammatory cytokines negatively impacts spatial
earning and synaptic plasticity. IL-1 profoundly affects several
ehaviours (Goshen and Yirmiya, 2009). The ﬁrst report of its ability
o inhibit hippocampal-dependent learning (Oitzl et al., 1993) was
onﬁrmed by several other groups (Gibertini et al., 1995; Barrientos
t al., 2002) identifying IL-1 as key to the inhibitory effect of LPS
n hippocampal function. It has also been shown that persistent
verexpression of IL-1 in the hippocampus results in poor per-
ormance in hippocampal-dependent tasks (Hein et al., 2009) and
s, predictably, associated with microglial activation (Moore et al.,
009). Chronic upregulation of IL-6 has also been demonstrated
o be associated with deﬁcits in learning and microglial activation
Heyser et al., 1997; Sparkman, 2006) although at least one recent
tudy does not entirely concur with this (Donegan et al., 2014).
In addition to age-related increased hippocampal concentra-
ions of IL-1, IL-6 and TNF, increases in IFN and IL-18 have
lso been reported (Grifﬁn, 2006). These cytokines were shown
o exert an inhibitory effect on long-term potentiation (LTP),
he most-commonly studied form of synaptic plasticity (the abil-
ty of synapses to respond to changes in their activity) (Lynch,
014; Maher et al., 2006; Curran and O’Connor, 2001; Kelly
t al., 2013). Interestingly, when the age-related microglial acti-
ation (which accompanies the increased expression of these
ytokines) is decreased by acute administration of minocycline
Grifﬁn, 2006) or IL-4 (Nolan, 2005), long term potentiation was
artially restored. Similarly, longer-term treatments of aged ani-
als with atorvastatin, rosiglitazone or the polyunsaturated fatty
cid, eicosapentaenoic acid (EPA), decreased microglial activation
nd improved the ability of aged animals to sustain synaptic plas-
icity (Clarke, 2008; Loane, 2009; Lynch et al., 2007), pointing to
 causal relationship between microglial activation and loss of
ynaptic function. The ﬁndings suggest that strategies which reduce
euroinﬂammation will improve the age-dependent deterioration
f the CNS function.
.2. Alzheimer’s disease
Age is the most signiﬁcant risk factor for developing AD (AD), the
ost common neurodegenerative disorder and the most common
ause of dementia. The prevalence of this still untreatable disorder
s rising, due to and the increase in the ageing population. It is the
stimated that there will be 106 million AD patients by the year
050 (Brookmeyer et al., 2007). Consequently, there is an urgent
eed for the development and characterisation of relevant animalnd Development 160 (2016) 54–68
models to facilitate preclinical drug development and translation
research through to human clinical trials.
The most widely used animal models of AD are models of a rare
form of autosomal dominant familial AD (FAD) which comprises
less than 1% of AD cases (see the currently available genetic models
at http://www.alzforum.org/research-models). The major advan-
tage of using such models is that genetic causes of FAD are known,
while the cause(s) of the most common sporadic AD (SAD) are still
unknown and are likely comprise multiple genetic and environ-
mental risk factors. Importantly, although the etiology of sporadic
and familial AD is different, both forms of AD develop indistinguish-
able clinical and neuropathological phenotype. This includes the
accumulation of the amyloid plaques, comprised of the aggregated
A peptides and hyperphosphorylated protein tau in neuroﬁbril-
lary tangles (NFTs).
The currently available single transgenic or multiple transgenic
FAD mice that express human mutated APP and/or PS1/2 genes do
not completely recapitulate AD pathology (reviewed in LaFerla et al.
(LaFerla and Green, 2012)). Although these FAD models show early
learning disability and cognitive impairment followed by the accu-
mulation of A and senile plaque formation they do not develop
NFTs in their brains (although some show hyperphosphorylation
of tau). More importantly, none of the models show profound neu-
ronal loss − a characteristic feature of human AD (reviewed in
Gotz (Gotz et al., 2007)). The amyloid cascade hypothesis predicts
that accumulation of A peptides precedes hyperphosphorylation
of tau and NFT formation, thus initiating the cascade of events
leading to synaptic loss and neurodegeneration. To better model
this, transgenic murine models have been developed that express
mutated human tau (i.e. MAPT mutation which causes frontotem-
poral dementia and does not cause AD) together with human
mutated APP and/or PS1/2 genes (Lewis et al., 2001; Oddo et al.,
2003; Oddo, 2003). Indeed, these mice show a characteristic senile
plaque formation which precedes formation of NFTs and are valu-
able models to monitor the interrelationship between A and
tau accumulation. Over the past two  decades, these transgenic
murine models of familial AD have signiﬁcantly contributed to our
understanding of the molecular mechanism(s) of the disease, drug
development and preclinical testing. However, numerous reported
failures of new treatments for AD in clinical trials indicate that the
use of genetic models of familial AD does not represent the com-
plete picture of AD in humans. Consequently, there is a pressing
need to develop other animal models relevant to the sporadic form
(SAD), which represents 99% of AD cases.
Although both forms of AD are highly inﬂuenced by ageing, FAD
is more aggressive in its progression and manifests at younger
age. Understanding the differences between SAD and FAD, and
the causes of the build-up in pathologies, may  be important in
developing models for evaluating interventions against the more
common SAD. Furthermore, we should consider incorporating the
use of animal models that deal with the issue of extensive neu-
ronal loss (already present in patients with mild-moderate AD and
causing cognitive impairment), with the current AD mouse mod-
els that primarily model AD pathologies. Such models will enable
identiﬁcation of treatments that target both cognition, due to neu-
ronal loss, and clearance of A and/or tau pathologies, and these
are predicted to be more successful than treatments that target the
pathology alone. As ageing is the major risk factor of sporadic AD,
any models must reﬂect pathology that develops with age rather
than genetic manipulation alone, such as occurs in current FAD
models. These models will be important in identiﬁcation of crit-
ical component(s) of the ageing process that drive AD pathology
and target them for the treatment/prevention (Table 3).
Animal models of the apolipoprotein E (apoE), in particular of
the apoE4 isoform which is the major genetic risk factor of SAD,
are of particular interest both for understanding the role of apoE4
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Table  3
The most widely used genetic mouse models of Alzheimer’s disease categorized by their clinical relevance and frequency in aged-oriented research use.
AD modela Genetic modiﬁcation Clinical Relevanceb Tested in
Aged Micec
Relevant Referencesd
PDAPP A PDGF-driven human APP minigene with the
V717F (Indiana) mutation.
Amyloid plaques in the hippocampus, cerebral
cortex.
Gliosis.
Dystrophic neurites. Decreased synaptic and
dendritic density in the hippocampus.
Memory deﬁcits.
Yes Sterniczuk et al.
(2010a),Sterniczuk et al.
(2010b),Jyoti et al. (2010)
Tg2576 The human APP gene (isoform 695) containing the
double mutation K670N, M671L (Swedish
mutation) under the control of the hamster prion
protein.
Amyloid plaques with some vascular amyloid.
Astrogliosis and microgliosis.
No tangles or neuronal loss.
Impaired spatial learning, working memory, and
contextual fear conditioning.
Yes Schrempf et al. (2014),Lima
et al. (2008),Dzirasa et al.
(2006)
APP23 Transgene containing human APP (isoform 751)
containing the Swedish (KM670/671NL) mutation
under the murine Thy1 promoter.
Amyloid plaques. Astrogliosis and microgliosis.
Dystrophic neurites containing
hyperphosphorylated tau (no neuroﬁbrillary
tangles).
Neuronal loss in the CA1 region of the
hippocampus.
Memory defects, anxiety, agression, aletred
circadian rhythm.
Yes Maloney et al. (2002),Gossan
et al. (2013),Ayadi et al. (2012)
APP/PS1 Human transgenes APP KM670/671NL and PSEN1
L166P, both under the control of the Thy1
promoter.
Amyloid plaques. Phosphorylated tau-positive
neuritic processes, but no neuroﬁbrillary tangles.
Microgliosis.
Cognitive deﬁcits in spatial learning and memory.
Irritability, depression, disturbance of motor
functions, anxiety.
No Miller et al. (2007)
3xtg AD Single-cell embryos from mice with knock-in of
PSEN1 with the PS1M146V mutation were injected
with two human transgenes (APP with the
Swedish mutation and MAPT with the P30IL
mutation). Transgenes integrated at a single locus
under the control of the mouse Thy1 promoter.
Age-related, progressive neuropathology including
amyloid plaques (accumulation of intraneuronal
A), neuroﬁbrillary tangles and microgliosis.
Cognitive impairment, episodic memory loss,
circadian changes, anxiety.
No neuronal loss in the hippocampus.
No Oddo et al. (2003)
5xFAD Two transgenes: mutant human APP with the APP
Swedish, Florida and London mutations and
containing the 5′ untranslated region driven by the
mouse Thy1 promoter and mutant human PSEN1
including the M146L and L286V mutations driven
by the mouse Thy1 promoter.
Amyloid plaques, including accumulation of
intraneuronal A.
Gliosis and synapse degeneration.
Neuron loss in cortical layer 5 and subiculum.
No neuroﬁbrillary tangles.
Age-dependent memory deﬁcits.
Motor phenotype and reduced anxiety.
No Ayadi et al. (2012)
a Most widely used genetic mouse models of Alzheimer’s disease are listed; for complete list of AD models please go to http://www.alzforum.org/.
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d Maximum of 5 relevant references listed; listed references include selected rele
n AD pathogenesis as well as for developing anti-ApoE4 strate-
ies (Holtzman et al., 2000; Michaelson, 2014). So far these studies
ave utilised apoE−/− mice (Holtzman et al., 2000; Bales et al.,
997; Bales, 1999) and mice expressing human apoE2, apoE3 or
poE4 (Holtzman et al., 2000; Fagan et al., 2002). Using knock-in
nd targeted replacement technologies, humanised ApoE murine
odels have been developed that express human ApoE2/3/4 genes
nder the control of the murine ApoE regulatory sequence (see the
urrently available models at http://www.taconic.com/transgenic-
ouse-model/). Humanised AD models thus may  represent a more
elevant model both for familial and sporadic AD as they express the
ene of interest under its endogenous promoter. Although human-
sed murine models would potentially be less acute than the current
ransgenic models and would need more “ageing” to develop the
D-like pathology, they could identify more relevant drug targets
o develop successful therapies against AD. As we evidence novel
enetic risk factors of SAD, in addition to apoE4 allele, other risk
enes may  also be used to better model SAD (reviewed in Medway
t al. (Medway and Morgan, 2014)).
.3. Cardiovascular diseasesAgeing is also one of the main risk factors in the development
f cardiovascular diseases (CVD) given that it causes functional
lterations in the vasculature as a result of deregulation of theodel development and characterization publications.
molecular longevity pathways. The ageing heart in mice is compa-
rable with that of humans (Dai and Rabinovitch, 2009) but generally
require an additional genetic modiﬁcation for atherosclerosis to
occur, as outlined below. Vascular ageing is particularly associated
with endothelial dysfunction, arterial stiffening and remodeling,
impaired angiogenesis, defective vascular repair, and an increased
prevalence of atherosclerosis (Erusalimsky, 2009; Lakatta and Levy,
2003; Novella et al., 2013). Experimental models of cardiovascular
ageing include senescence-accelerated mouse (SAM) model with
two substrains: SAM-prone (SAMP) and SAM-resistant (SAMR),
each of which exhibits characteristic disorders (Butterﬁeld and
Poon, 2005; Takeda et al., 1997). SAMP8 shows an age-related
deterioration of learning and memory at an earlier age, com-
pared with the senescence-accelerated resistant strain (SAMR1)
(Butterﬁeld and Poon, 2005). Vascular studies using these models
in male (Novensa, 2010) and female (Novella et al., 2013; Novensa,
2010; Novella, 2010) mice have shown morphological alterations
and mechanical and endothelial dysfunction, and they are suitable
models for the study of vascular physiological changes during age-
ing. In addition, studies in mouse models of genes associated with
ageing have also been used to understand the connection between
ageing and CVD progression. In particular, mice deﬁcient for Sir-
tuin1 (Sirt1), which would mimic  the decreased activity associated
with ageing, exhibit enhanced injury in response to ischemia reper-
fusion studies. Consistently, Sirt1 transgenic mice display reduced
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njury and cardiac Sirt1-overexpressing mice exhibited delayed car-
iomyopathies associated with ageing (summarized in (North and
inclair, 2012)).
Atherosclerosis is the most common cause of CVD. Mouse mod-
ls of this process have been generated by genetic manipulation
f lipoprotein metabolism genes which resulted in mice exhibit-
ng hypercholesterolemia and atherosclerosis, providing a useful
ool to study lesion progression. Thus, the low-density lipopro-
ein receptor-deﬁcient (Ldlr-/-) mouse (Ishibashi, 1993) is a model
f familiar hypercholesterolemia with a plasma lipoprotein pro-
le similar to humans and atheroma lesions induced by a high
aloric Western diet. The human apoB response to a high-fat
eeding (Purcell-Huynh, 1995). The most widely used atheroscle-
otic mouse model is the apolipoprotein E-deﬁcient (ApoE-/-) mice
Plump, 1992; Zhang et al., 1992; Onozuka, 2002; Hartley, 2000)
hat develops hypercholesterolemia and spontaneous atheroscle-
osis with a complexity in the lesions resembling those observed
n human atherosclerosis (Zaragoza, 2011). The combination of
poE-deﬁciency with inactivation of other genes has advanced
he knowledge of the underlying pathogenesis of the atheroscle-
otic process. Whilst this model has been very useful, the rapid
nset of atherosclerosis in the mouse model compared to humans
weeks versus years) limits the utility of the model in drug or treat-
ent development. Similarly, the ApoE-/- model does not take into
ccount the effects of ageing on the physiology and the inﬂamma-
ory response to atherosclerotic lesions; this appears as a serious
odeling shortcoming given a strong age-dependent evolution of
he immune system toward the pro-inﬂammatory environment.
espite the signiﬁcance of CVD in age-related diseases, few mouse
odels have been developed that integrate physiological ageing
lement as the basic setting. Available mouse CVD models are sum-
arized in Table 4.
Several experimental models and methods have been developed
o address other cardiac complications.
Heart failure (HF) is a complex syndrome than can be caused
y multiple factors, but the consequences of an ageing of the pop-
lation and the improvement of treatments for ischemic cardiac
isease, are aged patients at risk for HF. HF is characterized by a
ecreased ability of the heart to provide sufﬁcient cardiac output
o support the normal functions of the tissues because of impaired
lling and/or ejection of blood (Houser et al., 2012). Research to
dentify novel targets for HF therapy usually requires preclinical
esting in appropriate HF animal models.
HF models were originally developed in rats because of the
umerous potential advantages inherent in a small animal model
Patten and Hall-Porter, 2009), although the advent of transgenic
trategies has made the mouse an invaluable tool to study the
athogenesis of heart failure and to identify novel therapeutic tar-
ets. Whereas the rat models have been used extensively to explore
he potential for novel pharmacological or molecular agents for the
reatment of HF, using animal models can establish causality, con-
rm proof-of-principal for a particular therapeutic approach, and
elp people to understand the multifactorial bases for CVD (Yutzey
nd Robbins, 2007). Mouse models of HF are usually non geneti-
ally altered models subjected to experimental manipulations such
s coronary artery ligation, cardiac pressure overload, cardiac vol-
me  overload, viral myocarditis, or cardiotoxic cardiomyopathy
Wang et al., 2004). However, genetically engineered murine mod-
ls are being developed in which the genes involved are those
elated to a variety of proteins including cytoskeletal or sarcomeric
omponents, neurohumoral receptors, cell signalling molecules,
alcium-regulating proteins, and to extracellular matrix proteins
Wang et al., 2004).
In mice that have undergone coronary artery ligation the time
ourse of HF is affected not only by the infarcted area but also by the
ge of animals. Two-month-old C57BL/6N mice tolerate coronarynd Development 160 (2016) 54–68
artery occlusion without HF signs, whereas 14-month-old mice
develop HF, with only 36% of animals surviving for more than 8
weeks (Gould et al., 2002). The same limitation occurs with the mice
with homozygous null mutations in the high-density lipoprotein
receptor SR-BI (scavenger receptor class B, type I) and ApoE, a model
of hyperlipidaemia and atherosclerosis which manifests multiple
myocardial infarction and HF (Braun, 2002). These mice survive
only a few weeks after birth, limiting their use in HF research.
The senescence-accelerated strain, SAMP8, has also been pro-
posed as a suitable model for the study of cardiac ageing. SAMP8
mice have diastolic dysfunction associated with ageing similar to
that observed in humans (Reed et al., 2011), an increase in age-
associated oxidative damage in RNA and DNA in heart (Gan  et al.,
2012), alterations in glucose transport (Kurokawa et al., 1998), and
present pro-inﬂammatory cytokines associated with the pathogen-
esis of cardiovascular diseases (Forman et al., 2010, 2011).
2.4. Metabolic dysfunction
A variety of metabolic dysfunctions, such as impaired glucose
tolerance, insulin resistance (IR), and type 2 diabetes mellitus
(T2DM) develop with age. Persistence of diabetes increases the risk
of a cluster of chronic life-threatening metabolic diseases such CVD,
hepatic steatosis, chronic kidney disease and central nervous sys-
tem deterioration. The pathogenic mechanisms of age-associated
T2DM include impaired insulin secretion from  cells, loss of
proper insulin/insulin-like growth factor (IGF1)-signalling medi-
ated by the insulin receptor substrates (IRS) (White, 2014), and an
increase in body weight owing to a reduction in energy expenditure
and/or nutrient sensing associated with ageing (Manini, 2010). A
mechanistic insight of carbohydrate metabolism has been obtained
from mouse models with genetic manipulations in these pathways
(Taniguchi et al., 2006). Thus, mutant mice for db (Leprdb/db) or
ob (Lepob/ob) genes have a deﬁciency in the leptin hormone sens-
ing system and develop an early-onset obesity, hyperglycemia and
IR due to a slower rate of catabolism (Gonzalez-Navarro et al.,
2007). Other diabetes-related mouse models are the insulin recep-
tor (Insr)-deﬁcient mice which display severe hyperinsulinemia
but die within a few days after birth and the insulin receptor sub-
strate 1 (IRS1)-null mice (a downstream effector of insulin) which
develop mild IR. A mouse model that recapitulates most character-
istics of T2DM is the Irs2-deﬁcient mouse which is characterized
by IR, hyperinsulinemia, hyperglucemia and -cell failure.  Irs2-/-
females also develop obesity produced by dysregulation of lep-
tin sensitivity (Gonzalez-Navarro et al., 2007). In addition, mouse
models with double deﬁciencies in Insr or Irs2 genes in combina-
tion with ApoE- or LDLr-inactivation shed light into the underlying
pathogenesis of the relationship between CVD, lipid and carbohy-
drate metabolism deterioration and insulin-signalling (Baumgartl,
2006; Gonzalez-Navarro, 2007; Han, 2006; Gonzalez-Navarro et al.,
2008; Martinez-Hervas, 2014). These studies have shown that
impaired insulin/IGF1-signalling produces life-threatening dis-
eases in mice similar to those in humans. However, reduced
insulin/IGF1-signalling can extend life span in lower metazoans
and seem to be in conﬂict with the pathogenic effect in mouse and
humans (White, 2014). Recent studies in brain-speciﬁc Irs2-null
mice, which resulted in reduced insulin/IGF1 signalling, showed an
increased life-span despite glucose and energy homeostasis imbal-
ance and obesity demonstrating the key role of insulin/IGF1-IRS2
pathway in coordinating metabolism and longevity (Taguchi et al.,
2007).
The growth hormone receptor/binding protein (Ghr/bp) KO
(GHR-KO) mouse constitutes another relevant model to study reg-
ulation of insulin-associated signalling pathways during ageing.
GHR-KO mice display decreased GH hormonal signalling and hep-
atic production of insulin-like growth factor 1 (IGF-1), which leads
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Table  4
Mouse models displaying cardiovascular disease.
Mouse modela Cardiovascular alterationb Clinical
relevancec
Tested in
Aged Miced
Relevant Referencese
SAMP8 mice Mechanical and endothelial dysfunction; Diastolic
dysfunction and cardiac ﬁbrosis
yes no Novella et al. (2013),Butterﬁeld
and Poon (2005),Takeda et al.
(1997),Novensa (2010),Reed
et al. (2011)
Sirt1-/- mice Enhanced injury in ischemia reperfusion studies;
Dilated cardiomyopathy
no no Novella (2010),Miranda (2015)
Sirt1-Tg mice Delayed cardiomyopathy no Novella (2010)
Ldlr-/- mice Increased atherosclerosis yes no North and Sinclair (2012)
ApoB-Tg mice Increased atherosclerosis yes Ishibashi (1993)
apoE-/- mice Increased atherosclerosis; cardiomyopathy yes no Purcell-Huynh (1995),Plump
(1992),Zhang et al.
(1992),Onozuka (2002),Hartley
(2000)
VSMC-speciﬁc Sirt1-TgapoE-/- Increased DNA damage and atherosclerosis yes no Gao et al. (2014)
Foxo1-/-apoE-/- Endothelial dysfunction and atherosclerosis no no McDonnell et al. (2015)
a Most common experimental setups are listed.
b Impact of the genetic manipulation in the indicated metabolic characteristics.
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o a markedly reduced level of circulating IGF-1, reduced growth
ate and adult body weight (Zhou, 1997) as well as longer lifes-
an (Coschigano, 2003). GHR-KO animals also exhibit decreased
lasma insulin level and consequently, higher insulin sensitivity,
n part due to decreased proliferation of  cells (Liu, 2004). Of note,
peciﬁc suppression of insulin sensitivity in these mice attenuates
henotypic features of slow ageing (Arum, 2014).
Reactive oxygen species (ROS), mitochondrial by-products of
xidative energy metabolism, are considered to be important
rivers of the age-related decline; ROS can damage DNA directly
r indirectly, resulting in a wide variety of oxidative DNA lesions
hich accumulate with age in different tissues. In turn, mutations
ffecting DNA repair further lead to more lesions and premature
geing (Gurkar and Niedernhofer, 2015; Wang et al., 2012). As such,
ouse models bearing genetic mutations of antioxidant enzymes
ay  help in determining its effects on ageing and lifespan. For
nstance, transgenic mice overexpressing mitochondrial catalase
how increased lifespan and reduced oxidative damage (Schriner
t al., 2005). Still, different mouse models have described contra-
ictory and/or inconsistent results, suggesting that mutation of a
nique antioxidant enzyme or even that oxidative damage alone
ay  not contribute in full to the ageing phenotype and longevity.
evertheless, mitochondrial dysfunction appears to possess strong
echanistic links with age-induced metabolic dysfunction, includ-
ng impaired fatty acid oxidation (FAO), ROS-induced oxidative
amage, inﬂammation and diabetes (Gao et al., 2014; McDonnell
t al., 2015). Indeed, the decline in mitochondrial function dur-
ng ageing is concomitant with the development of hyperglycemia
nd hyperinsulinemia (Petersen et al., 2003), while the prevalence
f diabetes is increased in aged individuals. Sirtuin 3 (Sirt3) KO
ice present an excellent opportunity to study metabolic changes
ssociated with mitochondrial dysfunction. SIRT3 is a mitochon-
rial deacetylase that increases mitochondrial energy metabolism
y regulating ROS detoxiﬁcation, ATP generation, mitochondrial
ynamics, nutrient oxidation, and the mitochondrial unfolded
rotein response (UPR) (McDonnell et al., 2015; Brenmoehl and
oeﬂich, 2013). Therefore, SIRT3 plays a key role in regulating fat
etabolism and whole-body energy homeostasis; livers of SIRT3
O mice accumulate lipid and acylcarnitine metabolites and show
mpaired fatty acid oxidation (FAO) (Hirschey, 2010). Moreover,
hen placed on a high-fat diet (HFD), SIRT3 KO mice exhibit
ccelerated development of several hallmarks of the metabolic
yndrome, including weight gain, impaired glucose tolerance, andinsulin resistance. In fact, these mice also show hampered insulin
secretion in response to glucose, suggesting a diet-induced pancre-
atic  cell dysfunction and the likelihood of SIRT3 protecting  cells
from nutritional stress (Hirschey, 2011).
SAMP1 mice also display several features of dysfunctional
energy metabolism. For instance, aged SAMP1 mice display
lower oxygen consumption and fat oxidation in parallel with
higher plasma glucose, insulin, leptin, and lower adiponectin
concentrations, when compared with age-matched SAMR1 mice.
Additionally, decreased fatty acid catabolism in the muscles and
liver, and increased inﬂammation and oxidative stress in the
adipose tissue, constitute early events in ageing SAMP1 mice
(Haramizu et al., 2011). This characteristic underscores the useful-
ness of SAMP1 mice in studying factors impacting on the metabolic
syndrome during ageing.
The mammalian sodium-coupled citrate transporter NaCT
(mINDY), is predominantly expressed in the liver cells and acts as a
transporter of Krebs cycle intermediates (Rogers and Rogina, 2015).
Interestingly, mINDY−/− mice are protected from HFD-induced
and age-associated insulin resistance, at least in part, by activa-
tion of 5′ AMP-activated protein kinase (AMPK) and subsequent
induction of mitochondrial biogenesis via peroxisome proliferator-
activated receptor-gamma coactivator 1 alpha (PGC-1), leading to
augmented energy expenditure associated with an increased hep-
atic lipid oxidation and reduced lipogenesis (Birkenfeld, 2011). As
a result, mINDY−/− mice display reduced adiposity and liver and
skeletal muscle lipid accumulation. The above highlights the value
of this model in studying age-associated nonalcoholic fatty liver
disease (NAFLD), obesity, and type 2 diabetes.
Taurine depletion has been shown to accelerate skeletal mus-
cle senescence leading to early death in mice (Ito et al., 2014a)
and administration of taurine affords several beneﬁcial effects
in obesity and its comorbidities, including type 2 diabetes. Tau-
rine transporter (TauT) KO (TauTKO) mice exhibit lower body
weight and abdominal fat mass compared with WT  animals,
suggesting that they are resistant to ageing-dependent obesity
when maintained on a normal diet. In addition, they also possess
more pancreatic  cells and enhanced glucose disposal, despite
lower serum insulin levels, implying deterioration in tissue energy
metabolism (Ito et al., 2015). Finally, TauTKO mice also display
impaired metabolic adaptation to exercise in the skeletal muscles
(Ito et al., 2014b). As such, this model may help to better under-
stand to which extent the crosstalk between the different metabolic
62 S. Drechsler et al. / Mechanisms of Ageing and Development 160 (2016) 54–68
Table 5
Mouse models of metabolic dysfunction.
Genetic deﬁciencya Metabolic alteration and impact on life-spanb Clinical
relevancec
Tested in
Aged Miced
Relevant Referencese
Leprdb/db, Lepob/ob Impaired leptin sensing, insulin resistance, obesity and
diabetes
no no Taniguchi et al.
(2006),Gonzalez-Navarro et al.
(2007)
Insr-/- mice Severe hyperinsulinemia and death at few days of birth no no Taniguchi et al.
(2006),Gonzalez-Navarro et al.
(2007)
Irs1-/- mice Impaired insulin-signalling, mild insulin resistance no no Taniguchi et al.
(2006),Gonzalez-Navarro et al.
(2007)
Irs2-/- mice Insulin resistance, hyperinsulinemia, hyperglucemia and b-cell
failure and death within few months
yes no Taniguchi et al.
(2006),Gonzalez-Navarro et al.
(2007)
brain-speciﬁc Irs2-/- mice glucose and energy homeostasis imbalance, obesity and
delayed ageing
yes yes Taguchi et al. (2007)
LDLr-/-macrophageInsr-/- mice Insulin resistance and accelerated atherosclerosis yes no Han (2006)
apoE-/-Irs2-/-, apoE-/-Irs2+/- mice Metabolic syndrome features, increased inﬂammation and
increased atherosclerosis
yes no Baumgartl
(2006),Gonzalez-Navarro
(2007),Gonzalez-Navarro et al.
(2008),Martinez-Hervas (2014)
GHR-/- mice Decreased insulin levels, b-cell proliferation and body weight
and  longer lifespan and increased insulin sensitivity
yes yes Zhou (1997),Coschigano (2003)
mitCatalaseTg Decreased oxidative stress and delayed ageing no yes Schriner et al. (2005)
Sirt3-/- mice Increased energy metabolism and weight gain, insulin
resistance, b-cell dysfunction
no no McDonnell et al.
(2015),Brenmoehl and Hoeﬂich
(2013),Hirschey (2011)
SAMP1 Lower oxygen consumption, enhanced glucose, insulin, leptin
and decreased adiponectin
no yes Haramizu et al. (2011)
mINDY-/- mice Augmented energy expenditure and decreased lipogenesis no no Birkenfeld (2011)
TauT-/- mice Lower body weight, insulin levels and enhanced glucose
disposal
no no Ito et al. (2015)
a Most common experimental setups are listed.
b Impact of the genetic manipulation in the indicated metabolic characteristics.
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ic Relevance of each listed model applies to a corresponding human condition.
d Mice ≥ 18 months of age.
e Maximum of 5 relevant references listed.
issues impacts the development of obesity and/or diabetes with
geing.
Interestingly, mouse models of ageing genes have also been used
o investigate the tangled relationship between CVD, metabolic
erangement and ageing. In some of these studies Sirtuin 1
sirt1) was found to be protective in age-associated diseases. In
poE-/- mice, for example, the speciﬁc vascular Sirtuin 1 (Sirt1)
eﬁciency, accelerated atherosclerosis (Gorenne, 2013) or car-
iomyopathy (Planavila et al., 2012), while activation of the Sirt1
rovided atheroprotection in the same model (Miranda, 2015).
ice overexpressing Sirt1 or speciﬁc activation of Sirt1 protected
rom metabolic disorders such as diabetes and liver steatosis
nd mice displayed healthy ageing (Herranz, 2010; Feige, 2008).
ene inactivation of Foxo1, a transcription factor that regu-
ates longevity genes and is modulated by Sirt1, in apoE-/- mice
ggravated atherosclerosis and produced endothelial dysfunction
Qiang, 2012).
On the other hand, ablation of the genes Cdkn2a/Cdkn2b (whose
xpression increases with age (Krishnamurthy, 2004)) encoded by
he Ink4/Arf locus promoted atherosclerosis in apoE-/- and Ldlr-/-
ice (Gonzalez-Navarro, 2010; Kuo et al., 2011). Consistently, over-
xpression of the Cdkn2a/Cdkn2b genes restored insulin-signalling
nd sensitivity associated with ageing (Gonzalez-Navarro, 2013)
nd diminished hepatic steatosis and IR in 1 year-aged Irs2+/−
ice (Vinue, 2015). Therefore, these mouse studies indicate a pro-
ective role of Cdkn2a/Cdkn2b genes in metabolic age-associated
iseases. Telomere attrition, a process linked to ageing, restrained
roliferation of leukocytes and atheroma progression in apoE-/-
ice (Poch, 2004). The study of mouse models with metabolic
eﬁciencies either in lipid metabolism (in apoE, LDLr, apoB),
n insulin-signalling (GH/insulin/IGF1-signalling) and alteredmitochondrial dysfunction in combination or not with other age-
related processes (such as premature senescence, decreased or
absence of Sirtuins) have provided many mechanistic insight about
the ageing process and age-related chronic diseases. Most com-
monly used mouse models of metabolic derangements are listed in
Table 5.
2.5. Sleep and ageing
Ageing is characterized by impairments in physiological func-
tions, reduced ability to react adaptively to environmental stimuli
and increased susceptibility to disease (Troen, 2003; Vanhooren
and Libert, 2013), therefore it is not surprising that it brings with
it alterations in sleep physiology. The percentage of global elderly
population will increase in the next three decades and it has been
reported that over 40% of people over 65, suffer from sleep dis-
turbances (Foley et al., 2004). Normal ageing is accompanied by
changes in the sleep quality, its duration and architecture. Speciﬁ-
cally, a decrease in the proportion of the deeper, more restorative,
slow-wave sleep (SWS) and rapid eye movement (REM) sleep in
the healthy elderly has been suggested. Furthermore, sleep latency
and sleep fragmentation (waking up during the night) increments
with age, leading to an increase of risk of developing physical and
psychiatric illnesses. Indeed, sleep disturbance can induce depres-
sion (Jaussent et al., 2011; Tranah et al., 2010; Paudel et al., 2008)
and increase the risk of neurodegeneration (Singletary and Naidoo,
2011) and mortality (Cappuccio et al., 2010) in the elderly popula-
tion. Therefore, a crucial issue is to understand which risk factors
can lead to sleep disturbances. To gain a better insight into this rel-
evant question many mouse models have been developed to study
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he biology of ageing and neurodegeneration in association with
leep disturbances.
Experimental evidence suggests that sleep deprivation and dis-
urbances in circadian rhythms may  promote oxidative stress and
lay a role in the occurrence of hypertension, type 2 diabetes
nd neurodegenerative disorders. Most experimental evidence was
btained from different animal species, mainly rats and mice.
ecent ﬁndings show that severe astrogliosis, oxidative damage
nd synaptic degeneration occur in Bmal1 mouse model; deletion
n Bmal1 gene constitutes one of the core elements of the circa-
ian transcriptional-translational feedback loop (TTFL). These data
uggest that a decline in the circadian function, as seen in normal
geing, can exacerbate neurodegeneration via decreased BMAL1-
ediated transcription (Musiek et al., 2015).
Diabetes, hypertension and metabolic syndrome are well known
o-morbidities of neurodegenerative diseases frequently found in
he elderly. Although there are many different models of diabetes
heir sleep patterns have not been well studied and the related
vidence is scarce. The ob/ob mouse shows a sleep disordered
reathing that appears to exacerbate the already present pathol-
gy. The Zucker fatty rat is widely used in research to study type
 diabetes and shows mutation in the leptin receptor (Phillips
t al., 1996) leading to obesity, hyperphagia and hyperinsulinemia.
ig. 1. A summary ﬁgure highlighting the effects of ageing on different disease areas. Also
odels where appropriate. (Loffredo et al., 2013; Barrientos et al., 2015; Matt and Johns
iang  and Cadenas, 2014; Gorle et al., 2016; Minogue et al., 2014; Gomez et al., 2008; Kov
artin  et al., 2006; Turnbull et al., 2009; Lloréns et al., 2007).nd Development 160 (2016) 54–68 63
Recent evidence shows that Zucker fatty rats present a longer daily
period of SWS  suggesting that obesity and/or insulin resistance
inﬂuences sleep patterns (Megirian et al., 1998).
Disturbances of both sleep and circadian rhythms have
long been associated with many neurological and psychiatric
ageing-related diseases, including Alzheimer’s disease. Alzheimer’s
diseasepatients show alterations in sleep–wake cycle activity. As
described above, Alzheimer’s diseaseis the most common age-
related neurodegenerative disorder. Recent research has provided
evidence that chronic sleep restrictions can exacerbate A pathol-
ogy and can induce tau phosphorylation and synaptic injury in
mouse models of Alzheimer’s disease (Rothman et al., 2013; Di
Meco et al., 2014). Furthermore, recent studies in transgenic mice
demonstrated that an increase of amyloid deposition and tau intra-
cellular aggregation may  impair sleep patterns, and consequently
promote amyloid plaque formation. Abnormalities in the normal
sleep architecture consists of phase delay (Duncan et al., 2012),
altered nocturnal activity level (Sterniczuk et al., 2010a, 2010b) and
changes in non-REM sleep (Jyoti et al., 2010). Thus, Alzheimer’s dis-
easemouse models show sleep disturbances which are also present
in AD patients.
In addition to Alzheimer’s disease, Parkinson’s Disease is a
progressive disease of the nervous system marked by tremors,
 included are similarities or differences between human disease and current mouse
on, 2016; Ziebell et al., 2016; Ojo et al., 2015; Lynch, 2015; Salminen et al., 2011;
acs, 2009; Marti et al., 2007; Kumar et al., 2009; Starr et al., 2015; Kale et al., 2010;
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uscular rigidity, slow and imprecise movements. Parkinson’s Dis-
ase patients experience a severe impairment in normal sleep
ctivity characterized by insomnia, excessive daytime sleepi-
ess, increase number of nocturnal awakenings and REM-sleep
ehaviour disorder (Schrempf et al., 2014). Several ﬁndings, using
 dopamine-transporter KO mouse demonstrated a suppression of
ormal REM sleep (Lima et al., 2008; Dzirasa et al., 2006) although
otor functions were not affected by the diminished dopaminer-
ic tone. Furthermore, other evidence suggests that dopaminergic
eurons of the ventral mesencephalic tegmentum may  be impor-
ant for REM sleep (Maloney et al., 2002). In addition, it has been
emonstrated using rat model that blockage of dopaminergic D(2)
eceptors produced decrease of REM but not of the slow wave sleep
fter REM sleep deprivation (Lima et al., 2008). Thanks to recent
tudies carried out in rodent animal models, it can be suggested
hat PD and sleep may  be intertwined, either as predictors or con-
equences of dopaminergic neurodegeneration.
Neurodegenerative and metabolic disorders associated with
geing lead to sleep disturbances in humans. The opportunity
o reproduce age-related disorders with mutations and complex
enome manipulation, give the possibility to further investigate the
otential mechanisms that are responsible for sleep disturbances in
lderly patients. The importance of investigating multimorbidities
n mouse models is demonstrated by the observation that disrupted
ircadian rhythms can result in osteoarthritis (Gossan et al., 2013).
hus, it is entirely feasible that a disease such as Alzheimer’s dis-
ase can cascade through a disrupted circadian rhythm to promote
usceptibility to other type of diseases such as osteoarthritis with
he overarching age-related changes strongly contributing.
. Looking to the future
Mouse studies continue to deliver insight into disease through
 variety of physiological systems, and with the pressure of an age-
ng society it is certain that we will face an increased use of mice
n ageing studies in the near future. The inﬂuence of ageing in the
evelopment of selected disease is summarized in Fig. 1, includ-
ng areas where there are differences between current models and
atients. Ageing mouse studies, however present us with several
roblems, primarily cost and time. Ageing mice is expensive and
ime consuming, and results in difﬁculties in obtaining sufﬁcient
unding. It is therefore important to critically assess models on a
ontinuous basis to determine their utility for clinically-relevant
tudies and determine whether new models are needed and/or
eeper phenotypic information on existing models is required. This
s particularly relevant as we learn more about co-morbidities asso-
iated with individual diseases. Furthermore, to study an ageing
henotype within the conﬁnes of a standard three year project
rant would mean ideally having ageing mice already available
hen the grant starts, which is rarely feasible. There is therefore
 need for ﬂexibility in funding streams and funding proportionate
o the increased costs of ageing mice. However, as funding is always
ighly competitive, we must also explore mechanisms for cost sav-
ng. One potential for cutting costs, and allowing the immediate
vailability of aged animals, is to have a centralised access to age-
ng mice, which may  include the most common strains and models
f age-relevant conditions. Building on the theme of centralisation,
any studies are focused on a single phenotype and yet we often
bserve comorbidities in the aged (Fabbri et al., 2015), and there-
ore providing central facilities with a wide range pf phenotypic
apabilities will allow a deeper analysis of phenotypes in a single
odel. The range of phenotypes associated with ageing is empha-
ised by the limited examples of models highlighted above. Ideally,
 range of phenotypic assays would be applied to aged mouse mod-
ls to provide a centralised comprehensive phenotypic analysisnd Development 160 (2016) 54–68
of mutants under different test conditions, similar to the Mouse
Clinic model (Ayadi et al., 2012) or Intervention Testing Programme
(Miller et al., 2007; Warner et al., 2000). Developing such resources
will be a challenge but infrastructures supporting mouse research
(Consortium, 2015) provide a stepping stone and centralised exper-
tise and services would no doubt facilitate the study of ageing and
age-related disease. Furthermore, as highlighted here, more work is
needed to understand the relevance and utility of the various mod-
els to study age-related diseases. This effort will continue within the
recently formed MouseAGE COST action to provide this information
in an easily accessible form with consensus recommendations from
experts in the various ﬁelds.
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